 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | NKG2D-ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology, ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology
Trial completion date, Trial primary completion date: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 (clinicaltrials.gov) - Nov 16, 2020
P1/2, N=90, Recruiting, Sponsor: Chongqing Public Health Medical Center
Trial completion date: Sep 2020 --> Aug 2022 | Trial primary completion date: May 2020 --> Feb 2022
- | NKG2D-ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology, ACE2 CAR-NK cells / Chongqing Sidemu Biotechnology Technology
New P1/2 trial: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 (clinicaltrials.gov) - Mar 26, 2020
P1/2, N=90, Recruiting, Sponsor: Chongqing Public Health Medical Center